Obravnava bolnikov s sladkorno boleznijo v času epidemije covida-19
DOI:
https://doi.org/10.6016/ZdravVestn.3093Ključne besede:
sladkorna bolezen, covid-19, SARS-CoV-2, antidiabetiki, obravnava sladkorne bolezni med epidemijoPovzetek
Leto 2020 bo nedvomno zaznamovano s pandemijo koronavirusne bolezni 2019 (covid-19), ki jo povzroča novi koronavirus SARS-CoV-2. Izkazalo se je, da pri bolnikih s sladkorno boleznijo covid-19 poteka v hujši obliki; v večjem deležu je potrebno mehansko predihavanje, ugotavlja pa se tudi večja smrtnost. V prispevku opisujemo možne patofiziološke mehanizme, ki bi lahko bili povezani s hujšim potekom covida-19 pri bolnikih s sladkorno boleznijo. Navajamo tudi priporočila za uporabo oz. opustitev antidiabetičnih zdravil med okužbo in objavljamo navodila za prilagoditev vodenja te kronične bolezni med epidemijo. Opisujemo lastne izkušnje glede organiziranosti obravnave v diabetološki ambulanti Univerzitetnega kliničnega centra Ljubljana. Pri bolezni covid-19 je še veliko neznank, zato so na tem področju potrebne nadaljnje raziskave. Ne glede na to pa bodo ta priporočila za obravnavo bolnikov s sladkorno boleznijo med epidemijo prispevala k izboljšanju in optimizaciji obravnave bolnikov s sladkorno boleznijo tudi v obdobju, ko bo epidemija minila.
Prenosi
Literatura
1. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-50.
DOI: 10.1016/S2213-8587(20)30152-2
PMID: 32334646
2. WHO Coronavirus (COVID-19) Dashboard. Geneva: World Health Organization; 2020 [cited 2021 Mar 20]. Available from: https://covid19.who.int/.
3. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020;14(3):211-2.
DOI: 10.1016/j.dsx.2020.03.002
PMID: 32172175
4. Katulanda P, Dissanayake HA, Ranathunga I, Ratnasamy V, Wijewickrama PS, Yogendranathan N, et al. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. Diabetologia. 2020;63(8):1440-52.
DOI: 10.1007/s00125-020-05164-x
PMID: 32405783
5. Shenoy A, Ismaily M, Bajaj M. Diabetes and covid-19: a global health challenge. BMJ Open Diabetes Res Care. 2020;8(1):e001450.
DOI: 10.1136/bmjdrc-2020-001450
PMID: 32345580
6. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318(5):E736-41.
DOI: 10.1152/ajpendo.00124.2020
PMID: 32228322
7. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7):e3319.
DOI: 10.1002/dmrr.3319
PMID: 32233013
8. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42.
DOI: 10.1001/jama.2020.2648
PMID: 32091533
9. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500-15.
DOI: 10.1007/s00125-020-05180-x
PMID: 32472191
10. Wargny M, Gourdy P, Ludwig L, Seret-Bégué D, Bourron O, Darmon P, et al.; CORONADO investigators. Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study. Diabetes Care. 2020;43(11):e174-7.
DOI: 10.2337/dc20-1217
PMID: 32847826
11. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-22.
DOI: 10.1016/S2213-8587(20)30272-2
PMID: 32798472
12. Seiglie J, Platt J, Cromer SJ, Bunda B, Foulkes AS, Bassett IV, et al. Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized With COVID-19. Diabetes Care. 2020;43(12):2938-44.
DOI: 10.2337/dc20-1506
PMID: 32847827
13. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303-10.
DOI: 10.1016/j.dsx.2020.04.004
PMID: 32298981
14. COVID-19 sledilnik. Ljubljana: Luka Renko; 2021 [cited 2021 Jan 20]. Available from: https://covid-19.sledilnik.org/sl/stats.
15. Akash MS, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies. Arch Microbiol. 2020;202(5):953-65.
DOI: 10.1007/s00203-020-01818-x
PMID: 32016521
16. Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020;39:101044.
DOI: 10.1016/j.molmet.2020.101044
PMID: 32585364
17. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11-30.
DOI: 10.1038/s41574-020-00435-4
PMID: 33188364
18. Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol. 2009;302(2):193-202.
DOI: 10.1016/j.mce.2008.09.020
PMID: 18948167
19. Pal R, Bhansali A. COVID-19, diabetes mellitus and ACE2: the conundrum. Diabetes Res Clin Pract. 2020;162:108132.
DOI: 10.1016/j.diabres.2020.108132
PMID: 32234504
20. Smith SM, Boppana A, Traupman JA, Unson E, Maddock DA, Chao K, et al. Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. J Med Virol. 2020;93(1):409-15.
DOI: 10.1002/jmv.26227
PMID: 32589756
21. Pal R, Banerjee M, Yadav U, Bhattacharjee S. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature. Diabetes Metab Syndr. 2020;14(6):1563-9.
DOI: 10.1016/j.dsx.2020.08.015
PMID: 32853901
22. Cariou B, Goronflot T, Rimbert A, Boullu S, Le May C, Moulin P, et al. Routine use of statins and increased mortality related to COVID-19 in inpatients with type 2 diabetes: results from the CORONADO study. Diabetes Metab. 2020;47(2):101202.
DOI: 10.1016/j.diabet.2020.10.001
PMID: 33091555
23. Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020;32(2):176-187.e4.
DOI: 10.1016/j.cmet.2020.06.015
PMID: 32592657
24. Iacobellis G. COVID-19 and diabetes: can DPP4 inhibition play a role? Diabetes Res Clin Pract. 2020;162:108125.
DOI: 10.1016/j.diabres.2020.108125
PMID: 32224164
25. Ceriello A, Stoian AP, Rizzo M. COVID-19 and diabetes management: what should be considered? Diabetes Res Clin Pract. 2020;163:108151.
DOI: 10.1016/j.diabres.2020.108151
PMID: 32305399
26. Katulanda P, Dissanayake HA, Ranathunga I, Ratnasamy V, Wijewickrama PS, Yogendranathan N, et al. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. Diabetologia. 2020;63(8):1440-52.
DOI: 10.1007/s00125-020-05164-x
PMID: 32405783
27. Drucker DJ. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications. Endocr Rev. 2020;41(3):bnaa011.
DOI: 10.1210/endrev/bnaa011
PMID: 32294179
28. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020;384(8):693,704.
DOI: 10.1056/NEJMoa20214361
PMID: 32678530
29. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am J Emerg Med. 2020;38(7):1488-93.
DOI: 10.1016/j.ajem.2020.04.035
PMID: 32336586
30. Alessi J, de Oliveira GB, Schaan BD, Telo GH. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetol Metab Syndr. 2020;12(1):80.
DOI: 10.1186/s13098-020-00583-7
PMID: 32922517
31. Ma RC, Holt RI. COVID-19 and diabetes. Diabet Med. 2020;37(5):723-5.
DOI: 10.1111/dme.14300
PMID: 32242990
32. Rogers LC, Lavery LA, Joseph WS, Armstrong DG. All Feet On Deck-The Role of Podiatry During the COVID-19 Pandemic: preventing hospitalizations in an overburdened healthcare system, reducing amputation and death in people with diabetes. J Am Podiatr Med Assoc. 2020:1-11.
DOI: 10.7547/20-051
PMID: 32208983
33. Papanas N, Papachristou S. COVID-19 and Diabetic Foot: Will the Lamp Burn Bright? Int J Low Extrem Wounds. 2020;19(2):111.
DOI: 10.1177/1534734620921382
PMID: 32320324
Prenosi
Objavljeno
Številka
Rubrika
Licenca
Avtor na prispevku, ki ga bo pripravil za Zdravniški vestnik, po pogodbi nanj prenaša vse materialne avtorske pravice, kakor izhajajo iz 22. člena Zakona o avtorski in sorodnih pravicah, in sicer pravico reproduciranja, pravico javnega izvajanja, pravico javnega prenašanja, pravico javnega predvajanja s fonogrami in videogrami, pravico javnega prikazovanja, pravico radiodifuznega oddajanja, pravico radiodifuzne retransmisije, pravico sekundarnega radiodifuznega oddajanja, pravico dajanja na voljo javnosti, pravico predelave, pravico avdiovizualne priredbe, pravico distribuiranja ter pravico dajanja v najem in vse druge pravice avtorja v skladu z ZASP.
Avtorjev prenos pravic po pogodbi je neizključen, velja za neomejeno število izdaj, za ves čas trajanja materialnih avtorskih pravic ter je prostorsko neomejen.
Avtor sme avtorsko delo tudi sam izkoriščati ali avtorske pravice prenašati na tretje osebe, vendar oboje šele po preteku 3 mesecev od prve objave dela v reviji Zdravniški vestnik.
Avtor Zdravniškemu vestniku izrecno dovoli, da lahko pravice, pridobljene v skladu s pogodbo prenaša naprej na tretje osebe brez omejitev.
Avtor se strinja, da Zdravniški vestnik prispevek objavi pod pogoji licence Creative Commons BY-NC 4.0 (navedba avtorstva-nekomercialno) ali primerljive licence.
